

Curanex highlights patient cases suggesting its lead candidate may aid cachexia and severe disease recovery.
You can purchase shares of Curanex Pharmaceuticals (NASDAQ:CURX) through any online brokerage.
Other companies in Curanex Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
There is no analysis for Curanex Pharmaceuticals to provide a consensus price target.
The stock price for Curanex Pharmaceuticals (NASDAQ: CURX) is $6.19 last updated November 3, 2026 at 4:02 PM EST.
There are no upcoming dividends for Curanex Pharmaceuticals.
Curanex Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Curanex Pharmaceuticals.
Curanex Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications:...